The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Survivin: A molecular biomarker in cancer
Open accessAbstract
Survivin, a member of the inhibitor of apoptosis (IAP) protein family that inhibits caspases and blocks cell death, is highly expressed in most cancers and is associated with a poor clinical outcome. Survivin has consistently been identified by molecular profiling analysis to be associated with high tumour grade cancers, different disease survival and recurrence. Polymorphisms in the survivin gene are emerging as powerful tools to study the biology of the disease and have the potential to be used in disease prognosis and diagnosis. The survivin gene polymorphisms have also been reported to influence tumour aggressiveness as well as survival of cancer patients. The differential expression of survivin in cancer cells compared to normal tissues and its role as a nodal protein in a number of cellular pathways make it a high target for different therapeutics. This review discusses the complex circuitry of survivin in human cancers and gene variants of survivin, and highlights novel therapy that targets this important protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., & Hemminki, K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430201 · Cited by 4,114
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Tamm, I., Wang, Y., Sausville, E. A., Scudiero, D. A., Vigna, N. J., Oltersdorf, T., & Reed, J. C. (1998) · PubMed · Cited by 1,397
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Survivin, versatile modulation of cell division and apoptosis in cancer
Altieri, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207113 · Cited by 900
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., & Murphy, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106643200 · Cited by 794
dbSNP—database for single nucleotide polymorphisms and other classes of minor genetic variation
Sherry, S. T., Ward, M., & Sirotkin, K. (1999) · Genome Research · doi:10.1101/gr.9.8.677 · Cited by 789
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas
田中, 慶. (2000) · Medical Entomology and Zoology · doi:10.11501/3179364 · Cited by 559
Mirza, A., McGuirk, M., Hockenberry, T. N., Wu, Q., Ashar, H., Black, S., Wen, S. F., Wang, L., Kirschmeier, P., Bishop, W. R., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205353 · Cited by 530
Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice
Schimmer, A. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1918 · Cited by 512
Apoptosis-targeted therapies for cancer
Reed, J. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00241-6 · Cited by 500
Monzó, M., Rosell, R., Felip, E., Astudillo, J., Sánchez, J. J., Maestre, J., Martín, C., Font, A., Barnadas, A., & Abad, A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2100 · Cited by 487
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
An IAP-IAP Complex Inhibits Apoptosis
Dohi, T., Okada, K., Xia, F., Wilford, C. E., Samuel, T., Welsh, K., Marusawa, H., Zou, H., Armstrong, R., Matsuzawa, S.-I., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400236200 · Cited by 398
Survivin: A new target for anti-cancer therapy
Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 379
Structural, functional and therapeutic biology of survivin
Sah, N. K., Khan, Z., Khan, G. J., & Bisen, P. S. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.03.007 · Cited by 355
Survivin promotes cell proliferation in human hepatocellular carcinoma
Ito, T., Shiraki, K., Sugimoto, K., Yamanaka, T., Fujikawa, K., Ito, M., Takase, K., Moriyama, M., Kawano, H., Hayashida, M., et al. (2000) · Hepatology · doi:10.1053/he.2000.6496 · Cited by 329
Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma
Sarela, A. I. (2000) · Gut · doi:10.1136/gut.46.5.645 · Cited by 323
Initial apoptosis is followed by increased proliferation of apoptosis‐resistant endothelial cells
Sakao, S., Taraseviciene‐Stewart, L., Lee, J. D., Wood, K., Cool, C. D., & Voelkel, N. F. (2005) · The FASEB Journal · doi:10.1096/fj.04-3261fje · Cited by 301
Survivin apoptosis: an interloper between cell death and cell proliferation in cancer.
Altieri, D. C., Marchisio, P. C., & Marchisio, C. (1999) · PubMed · Cited by 289
Satoh, K., Kaneko, K., Hirota, M., Masamune, A., Satoh, A., & Shimosegawa, T. (2001) · Cancer · doi:10.1002/1097-0142(20010715)92:2<271::aid-cncr1319>3.0.co;2-0 · Cited by 256
p21/CDKN1A Mediates Negative Regulation of Transcription by p53
Löhr, K., Möritz, C., Contente, A., & Dobbelstein, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212517200 · Cited by 227
Tsuruma, T., Hata, F., Torigoe, T., Furuhata, T., Idenoue, S., Kurotaki, T., Yamamoto, M., Yagihashi, A., Ohmura, T., Yamaguchi, K., et al. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-19 · Cited by 181
Targeting survivin in cancer therapy
Pennati, M., Folini, M., & Zaffaroni, N. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.4.463 · Cited by 180
Sarela, A. I., Verbeke, C. S., Ramsdale, J., Davies, C. L., Markham, A. F., & Guillou, P. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600133 · Cited by 178
Survivin: A Protein with Dual Roles in Mitosis and Apoptosis
WHEATLEY, S., & MCNEISH, I. (2005) · International Review of Cytology · doi:10.1016/s0074-7696(05)47002-3 · Cited by 168
p53 Regulation of G 2 Checkpoint Is Retinoblastoma Protein Dependent
Flatt, P. M., Tang, L. J., Scatena, C. D., Szak, S. T., & Pietenpol, J. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.12.4210-4223.2000 · Cited by 161
Aberrant Regulation of Survivin by the RB/E2F Family of Proteins
Jiang, Y., Saavedra, H. I., Holloway, M. P., Leone, G., & Altura, R. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404496200 · Cited by 160
Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma
Grabowski, P., Kühnel, T., Mühr-Wilkenshoff, F., Heine, B., Stein, H., Höpfner, M., Germer, C. T., & Scherübl, H. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600696 · Cited by 158
Autologous Dendritic Cell Vaccines for Non–Small-Cell Lung Cancer
Hirschowitz, E. A., Foody, T., Kryscio, R., Dickson, L., Sturgill, J., & Yannelli, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.074 · Cited by 158
Identification of a novel splice variant of the human anti-apoptopsis gene survivin
Badran, A., Yoshida, A., Ishikawa, K., Goi, T., Yamaguchi, A., Ueda, T., & Inuzuka, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.178 · Cited by 150
Hsieh, J.-K., Yap, D., O’Connor, D. J., Fogal, V., Fallis, L., Chan, F., Zhong, S., & Lü, X. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.78-93.2002 · Cited by 145
Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions
Nasr, M. R., & El-Zammar, O. A. (2008) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181624054 · Cited by 131
Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle‐Teijeiro, J., Medeiros, R., & Schmitt, F. C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-32 · Cited by 127
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin
Otto, K., Andersen, M. H., Eggert, A. O., Keikavoussi, P., Pedersen, L. Ø., Rath, J. C., Böck, M., Bröcker, E., Straten, P. T., Kämpgen, E., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.08.007 · Cited by 112
Krepela, E. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000464 · Cited by 109
Solution Structure of Human Survivin and Its Binding Interface with Smac/Diablo
Sun, C. C., Nettesheim, D. G., Liu, Z., & Olejniczak, E. T. (2004) · Biochemistry · doi:10.1021/bi0485171 · Cited by 109
Targeted therapy by disablingcrossroadsignaling networks: the survivin paradigm
Altieri, D. C. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0436 · Cited by 103
Polymorphisms in the survivin gene and the risk of lung cancer
Jang, J. S., Kim, K. M., Kang, K. H., Choi, J. E., Lee, W. K., Kim, C. H., Kang, Y. M., Kam, S., Kim, I., Jun, J. E., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.09.008 · Cited by 102
O’Connor, D. J., Lam, E. W. ‐., Griffin, S., Zhong, S., Leighton, L. C., Burbidge, S. A., & Lü, X. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00309.x · Cited by 99
Survivin Signaling in Clinical Oncology: A Multifaceted Dragon
Kanwar, J. R., Kamalapuram, S. K., & Kanwar, R. K. (2012) · Medicinal Research Reviews · doi:10.1002/med.21264 · Cited by 98
The common germline Arg72Pro polymorphism of p53 and increased longevity in humans
Bojesen, S. E., & Nordestgaard, B. G. (2008) · Cell Cycle · doi:10.4161/cc.7.2.5249 · Cited by 93
Oncoapoptotic signaling and deregulated target genes in cancers: Special reference to oral cancer
Khan, Z., & Bisen, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.04.002 · Cited by 90
Transcriptional expression of survivin and its splice variants in brain tumors in humans
Yamada, Y., Kuroiwa, T., Nakagawa, T., Kajimoto, Y., Dohi, T., Azuma, H., Tsuji, M., Kami, K., & Miyatake, S. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.99.4.0738 · Cited by 89
Survivin regulates the p53 tumor suppressor gene family
Wang, Z., Fukuda, S., & Pelus, L. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207992 · Cited by 87
A Survivin Gene Signature Predicts Aggressive Tumor Behavior
Salz, W., Eisenberg, D., Plescia, J., Garlick, D. S., Weiss, R. M., Wu, X., Sun, T., & Altieri, D. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4284 · Cited by 84
Prognostic Significance of p53 Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma
Katkoori, V. R., Xu, J., Shanmugam, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1719 · Cited by 83
Targeting Survivin in Cancer: Novel Drug Development Approaches
Groner, B., & Weiß, A. (2013) · BioDrugs · doi:10.1007/s40259-013-0058-x · Cited by 81
Survivin -31G/C promoter polymorphism and sporadic colorectal cancer
Gazouli, M., Tzanakis, Ν., Rallis, G., Theodoropoulos, G. E., Papaconstantinou, I. G., Kostakis, A. G., Anagnou, N. P., & Nikiteas, N. I. (2008) · International Journal of Colorectal Disease · doi:10.1007/s00384-008-0601-2 · Cited by 72
Li, Y., Wang, J., Jiang, F., Lin, W., & Meng, W. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-1 · Cited by 70
Detection of survivin and p53 in human oral cancer: Correlation with clinicopathologic findings
Khan, Z., Tiwari, R. P., Mulherkar, R., Sah, N. K., Prasad, G. B. K. S., Shrivastava, B. R., & Bisen, P. S. (2009) · Head & Neck · doi:10.1002/hed.21071 · Cited by 58
Increased expression of survivin in gastric cancer patients and in first degree relatives
Yu, J. Q., Leung, W. K., Ebert, M. P., Ng, E. K. W., Go, M. Y. Y., Wang, H. B., Chung, S., Malfertheiner, P., & Sung, J. J. �. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600421 · Cited by 57
Survivin mRNA expression in patients with breast cancer.
Nasu, S., Yagihashi, A., Izawa, A., et al. (2002) · PubMed · Cited by 49
Theodoropoulos, G. E., Michalopoulos, N. V., Panoussopoulos, S.-G., Τaka, S., & Gazouli, M. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181d705d4 · Cited by 47
Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility
Kawata, N., Tsuchiya, N., Horikawa, Y., Inoue, T., Tsuruta, H., Maita, S., Satoh, S., Mitobe, Y., Narita, S., & Habuchi, T. (2010) · International Journal of Cancer · doi:10.1002/ijc.25850 · Cited by 44
Chemically synthesized human survivin does not inhibit caspase‐3
Li, C., Wu, Z., Liu, M., Pazgier, M., & Lu, W. (2008) · Protein Science · doi:10.1110/ps.036145.108 · Cited by 37
Li, W., Fan, J., & Bertino, J. R. (2001) · PubMed · Cited by 37
XIAP is not required for human tumor cell survival in the absence of an exogenous death signal
Sensintaffar, J., Scott, F. L., Peach, R., & Hager, J. H. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-11 · Cited by 23
Hsieh, Y., Tsai, C., Yeh, C., Yang, S., Hsieh, Y., & Weng, C. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2123-3 · Cited by 22
Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression
Lauxen, I. D. S., Oliveira, M., Rados, P. V., Lingen, M. W., Nör, J., & Filho, M. S. (2013) · Oral Diseases · doi:10.1111/odi.12136 · Cited by 14
Cited by
Yu, T., Li, Y., Gu, X., & Li, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.532457 · Cited by 94
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Turner, T. H., Alzubi, M. A., & Harrell, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58438-0 · Cited by 50
An OX-Tra’Ordinary tale: the role of OX40 and OX40L in atopic dermatitis
Sadrolashrafi, K., Guo, L., Kikuchi, R., Hao, A., Yamamoto, R. K., Tolson, H. C., Bilimoria, S. N., Yee, D. K., & Armstrong, A. W. (2024) · Cells · doi:10.3390/cells13070587 · Cited by 28
Geisen, M. E., Tessmann, J. W., Kelson, C. O., He, D., Wang, C., Faisal, A. S. M., Beswick, E. J., Baca, Y., Rock, S., Kolesar, J. M., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101283
“Resistant cells showed accelerated growth in vitro and in vivo , with increased Cyclin D1 and survivin, proteins known to drive apoptosis resistance, cell-cycle checkpoint bypass, and therapy resistance [16,17].”
Metadata
- Authors
- Mittal, R., Jaiswal, P., & Goel, A.
- Venue
- Indian Journal of Medical Research
- Publisher
- Scientific Scholar
- Published
- 2015
- Volume
- 141
- Issue
- 4
- Pages
- 389
- ISSN
- 0971-5916 (ISSN-L)
- OpenAlex
- W1853943513
- Cited by
- 352
- References
- 64
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.